Will Insulet Beat These Analyst Estimates?
Insulet (NAS: PODD) is expected to report Q4 earnings around Feb. 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Insulet's revenues will grow 24.8% and EPS will remain in the red.
The average estimate for revenue is $58.9 million. On the bottom line, the average EPS estimate is -$0.21.
Last quarter, Insulet reported revenue of $54.8 million. GAAP reported sales were 23% higher than the prior-year quarter's $44.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.26. GAAP EPS were -$0.26 for Q3 against -$0.29 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 44.5%, 290 basis points better than the prior-year quarter. Operating margin was -15.5%, 640 basis points better than the prior-year quarter. Net margin was -22.7%, 770 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $212.7 million. The average EPS estimate is -$1.07.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 72 members out of 113 rating the stock outperform, and 41 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give Insulet a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $22.91.
Is Insulet the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Insulet to My Watchlist.
The article Will Insulet Beat These Analyst Estimates? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.